Abiopharma

Castle Biosciences - New Data at American Foregut Societys 2025 Annual Meeting Demonstrates TissueCypher® Can Detect High-Risk Barrett’s Esophagus Patients Not Identified by Pathology to Support Improved Care Decisions

New Form 6-K - GH Research PLC Filed: 2025-09-09 AccNo: 0001140361-25-034360 Size: 434 KB

New Form 6-K - EDAP TMS SA Filed: 2025-09-09 AccNo: 0001171843-25-005786 Size: 8 MB

ScaleReady Awards G-Rex® Grants to Support Cell and Gene Therapy Manufacturing in California

Libtayo® (cemiplimab) Plus Chemotherapy Results at Five Years Reinforce Significant and Durable Improvements in Survival Outcomes for Advanced Non-small Cell Lung Cancer

Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress

New Data at American Foregut Societys 2025 Annual Meeting Demonstrates TissueCypher® Can Detect High-Risk Barrett’s Esophagus Patients Not Identified by Pathology to Support Improved Care Decisions

Breckenridge Brewery Awarded Silver Certification by the Colorado Green Business Network for Excellence in Sustainability Practices

Harvard Bioscience Announces Appointment of Stephen DeNelsky to Board of Directors

Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calciums Dose Strengths in Progressive Multiple Sclerosis

Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium’s Dose Strengths in Progressive Multiple Sclerosis

New Form 8-K - Tourmaline Bio, Inc. Filed: 2025-09-09 AccNo: 0001193125-25-198747 Size: 933 KB Item 1.01: Entry into a Material Definitive Agreement Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

New Form 8-K - Sintx Technologies, Inc. Filed: 2025-09-09 AccNo: 0001493152-25-012834 Size: 820 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 9.01: Financial Statements and Exhibits

New Form EFFECT - Immuneering Corp Filed: 2025-09-08 AccNo: 9999999995-25-002880 Size: 1 KB

New Form EFFECT - Scinai Immunotherapeutics Ltd. Filed: 2025-09-08 AccNo: 9999999995-25-002864 Size: 1 KB